1. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission
by Xiao-Jun Huang, Hong-Hu Zhu, Ying-Jun Chang, Lan-Ping Xu, Dai-Hong Liu, Xiao-Hui Zhang, Bin Jiang, Qian Jiang, Hao Jiang, Yu-Hong Chen, Huan Chen, Wei Han, Kai-Yan Liu, and Yu Wang
Blood
Volume 119(23):
June 7, 2012
©2012 by American Society of Hematology

2. Overview of patients included in the analysis by risk classification, HLA typing, and donor availability.
Overview of patients included in the analysis by risk classification, HLA typing, and donor availability. AML indicates acute myeloid leukemia; CR, complete remission; HSCT, hematopoietic stem-cell transplantation. HRD, haploidentical related donor; MSD, matched sibling donor; and MUD, matched unrelated donor.
Xiao-Jun Huang et al. Blood 2012;119:
©2012 by American Society of Hematology

3. CIR in all 132 patients with intermediate- and high-risk AML in CR1.
Xiao-Jun Huang et al. Blood 2012;119:
©2012 by American Society of Hematology

4. OS and DFS of all 132 patients with intermediate- and high-risk AML in CR1.
Xiao-Jun Huang et al. Blood 2012;119:
©2012 by American Society of Hematology

5. CIR of the HRD-HSCT group and the chemotherapy-alone group of patients with intermediate- and high-risk AML.
CIR of the HRD-HSCT group and the chemotherapy-alone group of patients with intermediate- and high-risk AML.
Xiao-Jun Huang et al. Blood 2012;119:
©2012 by American Society of Hematology

6. HRD-HSCT group and the chemotherapy-alone group of patients with intermediate- and high-risk AML. DFS (A) and OS (B).
HRD-HSCT group and the chemotherapy-alone group of patients with intermediate- and high-risk AML. DFS (A) and OS (B).
Xiao-Jun Huang et al. Blood 2012;119:
©2012 by American Society of Hematology